HumanaMedicare Advantage · Prior Auth · Medicare Advantage · Endocrinology, Family Medicine, Internal Medicine +1 moreMedium impact
DPP-IV, SGLT2 Combination Products (Revised)
Act
by Jan 1, 2026
Effective date
Jan 1, 2026
Identified
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for DPP-IV/SGLT2 combination diabetes medications (Steglujan, Qtern, and generic dapagliflozin-saxagliptin) effective January 1, 2026. Patients must have tried individual DPP-4 or SGLT2 inhibitors first, or have contraindications to them.
Get alerts when payers change rules like this one
We check Humana and other payers every day and email you when a change matches your specialty and state.
01Billing team must update prior authorization system to require preapproval for Steglujan, Qtern, and dapagliflozin-saxagliptin tablets for Humana Medicare Advantage patients.
02Providers must document previous treatment with or contraindications to individual DPP-4 inhibitors (sitagliptin, linagliptin) or SGLT2 inhibitors (empagliflozin, dapagliflozin) before prescribing combination products.
03Update EMR templates to include diabetes medication history documentation.
Original notice
DPP-IV, SGLT2 Combination Products (Revised)
mcp.humana.com · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.